GRCE

Grace Therapeutics, Inc. (GRCE) - 10-Q Summary

Business Context and Reporting Period

Reporting Period: Quarterly period ended September 30, 2025 (Q2 Fiscal 2026).

Business Overview: Grace Therapeutics is a clinical-stage biopharmaceutical company focused on rare and orphan diseases. The company recently changed its name from Acasti Pharma Inc. and domesticated to Delaware. Its primary focus is the development of GTx-104, an injectable formulation of nimodipine for aneurysmal subarachnoid hemorrhage (aSAH). Other candidates, GTx-102 (Ataxia Telangiectasia) and GTx-101 (Postherpetic Neuralgia), are currently deprioritized pending additional funding or partnerships.

Key Milestone: The FDA accepted the New Drug Application (NDA) for GTx-104 on August 22, 2025, with a Prescription Drug User Fee Act (PDUFA) target date of April 23, 2026.

Key Financial Metrics

Cash Flow (Six Months Ended Sept 30, 2025): Net cash used in operating activities was $4,944. There were no investing activities. Net cash used in financing activities was $327 (payment of stock issuance costs).

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased significantly to $938 for the quarter (from $3,432 in the prior year quarter) and $4,301 for the six months (from $6,049). This improvement was driven primarily by a $2,408 decrease in R&D expenses due to the completion of the pivotal Phase 3 STRIVE-ON trial for GTx-104.
• Derivative Warrant Liability: The company recognized a gain of $1,427 in the quarter and $940 for the six months due to the change in fair value of derivative warrant liabilities. This was largely attributable to the expiration of certain 2023 Common Warrants following the FDA's acceptance of the GTx-104 NDA.
• Income Tax Benefit: Unlike the prior year periods which recorded income tax benefits ($852 and $1,576 respectively), the company recorded no income tax benefit for the current periods due to the establishment of a partial valuation allowance against net domestic deferred tax assets.
• Capital Raise: In February 2025, the company completed a private placement raising net proceeds of $13,705. In October 2025 (subsequent event), the company received an additional $4,000 from the exercise of common warrants.

Guidance, Outlook, and Risks

• Liquidity: Management believes existing cash and cash equivalents ($16.9 million as of Sept 30, 2025) are sufficient to sustain planned operations for at least 12 months from the filing date. However, the company expects to incur continued operating losses and will require additional capital to fund daily operations beyond that period.
• Outlook: The company is focused on the FDA review of GTx-104. If approved, plans include building a commercial team and launching the product. Development of GTx-102 and GTx-101 remains contingent on securing additional funding or strategic partnerships.
• Risks:
  • Regulatory Uncertainty: No guarantee that GTx-104 will receive FDA approval by the PDUFA date or at all.
  • Capital Requirements: Inability to raise additional capital on acceptable terms could force the company to delay, scale back, or cease operations.
  • Single Product Dependence: The company is heavily dependent on the success of GTx-104.
  • Manufacturing: Reliance on third-party contract manufacturers (CMOs) and contract research organizations (CROs) introduces supply chain and quality control risks.

Investor Verification Checklist

• FDA PDUFA Date: Verify the April 23, 2026 target date for GTx-104 approval and monitor for any FDA requests for additional information that could delay this timeline.
• Cash Runway: Confirm the 12-month liquidity runway estimate against actual burn rates, noting the company's history of operating losses.
• Warrant Expirations: Review the terms of the 2023 and 2025 warrants, specifically the expiration triggers tied to FDA NDA acceptance/approval, to assess potential dilution or liability changes.
• Valuation Allowance: Understand the impact of the partial valuation allowance on deferred tax assets and its effect on future net loss calculations.
• Commitments: Note the $335 in committed payments to CMOs and CROs for the next 12 months as a baseline for near-term cash outflows.